Neuroimaging studies have indicated that altered cerebral blood flow (CBF) was associated with the long-term symptoms of postacute sequelae of SARS-CoV-2 infection (PASC), also known as “long COVID”. COVID-19 and long COVID were found to be strongly associated with host gene expression. Nevertheless, the relationships between altered CBF, clinical symptoms, and gene expression in the central nervous system (CNS) remain unclear in individuals with long COVID. This study aimed to explore the genetic mechanisms of CBF abnormalities in individuals with long COVID by transcriptomic-neuroimaging spatial association. Lower CBF in the left frontal-temporal gyrus was associated with higher fatigue and worse cognition in individuals with long COVID. This CBF pattern was spatially associated with the expression of 2,178 genes, which were enriched in the molecular functions and biological pathways of COVID-19. Our study suggested that lower CBF is associated with persistent clinical symptoms in long COVID individuals, possibly as a consequence of the complex interactions among multiple COVID-19-related genes, which contributes to our understanding of the impact of adverse CNS outcomes and the trajectory of development to long COVID.
Wulf HansonSAbbafatiCAertsJG, et al.
Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA2022;
328: 1604–1615.
2.
CebanFLingSLuiLMW, et al.
Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun2022;
101: 93–135.
3.
FogartyHTownsendLMorrinH, et al.
Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost2021;
19: 2546–2553.
LibbyPLüscherT.COVID-19 is, in the end, an endothelial disease. Eur Heart J2020;
41: 3038–3044.
6.
QiaoHDengXQiuL, et al.
SARS-CoV-2 induces blood-brain barrier and choroid plexus barrier impairments and vascular inflammation in mice. J Med Virol2024;
96: e29671.
7.
GreeneCConnollyRBrennanD, et al.
Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nat Neurosci2024;
27: 421–432.
8.
Silva AndradeBSiqueiraSde Assis SoaresWR, et al.
Long-COVID and Post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses2021;
13: 13.
9.
NicolaiLKaiserRStarkK.Thromboinflammation in long COVID-the elusive key to postinfection sequelae?J Thromb Haemost2023;
21: 2020–2031.
10.
WirthKJScheibenbogenCPaulF.An attempt to explain the neurological symptoms of myalgic encephalomyelitis/chronic fatigue syndrome. J Transl Med2021;
19: 471.
11.
MarcicMMarcicLLovric KojundzicS, et al.
Chronic endothelial dysfunction after COVID-19 infection shown by transcranial color-coded doppler: a cross-sectional study. Biomedicines2022;
10: 10.
12.
PetcharunpaisanSRamalhoJCastilloM.Arterial spin labeling in neuroimaging. World J Radiol2010;
2: 384–398.
13.
AjčevićMIscraKFurlanisG, et al.
Cerebral hypoperfusion in post-COVID-19 cognitively impaired subjects revealed by arterial spin labeling MRI. Sci Rep2023;
13: 5808.
14.
KimWSHJiXRoudaiaE, et al.
MRI assessment of cerebral blood flow in nonhospitalized adults who self-isolated due to COVID-19. J Magn Reson Imaging2023;
58: 593–602.
15.
QinYWuJChenT, et al.
Long-term microstructure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations. J Clin Invest2021;
131
16.
SenSNewman-NorlundRRiccardiN, et al.
Cerebral blood flow in patients recovered from mild COVID-19. J Neuroimaging2023;
33: 764–772.
17.
InitiativeC-HG.Mapping the human genetic architecture of COVID-19. Nature2021;
600: 472–477.
18.
Pairo-CastineiraEClohiseySKlaricL, et al.
Genetic mechanisms of critical illness in COVID-19. Nature2021;
591: 92–98.
19.
InitiativeC-HG.A first update on mapping the human genetic architecture of COVID-19. Nature2022;
608: E1–e10.
20.
InitiativeC-HG.A second update on mapping the human genetic architecture of COVID-19. Nature2023;
621: E7–e26.
21.
ZhuDZhaoRYuanH, et al.
Host genetic factors, comorbidities and the risk of severe COVID-19. J Epidemiol Glob Health2023;
13: 279–291.
22.
UdomsinprasertWNontawongNSaengsiwarittW, et al.
Host genetic polymorphisms involved in long-term symptoms of COVID-19. Emerg Microbes Infect2023;
12: 2239952.
23.
ScialoFDanieleAAmatoF, et al.
ACE2: the major cell entry receptor for SARS-CoV-2. Lung2020;
198: 867–877.
24.
LukiwWJPogueAHillJM.SARS-CoV-2 infectivity and neurological targets in the brain. Cell Mol Neurobiol2022;
42: 217–224.
25.
McCrackenIRSagincGHeL, et al.
Lack of evidence of angiotensin-converting enzyme 2 expression and replicative infection by SARS-CoV-2 in human endothelial cells. Circulation2021;
143: 865–868.
26.
YangRCHuangKZhangHP, et al.
SARS-CoV-2 productively infects human brain microvascular endothelial cells. J Neuroinflammation2022;
19: 149.
27.
ClaassenJThijssenDHJPaneraiRB, et al.
Regulation of cerebral blood flow in humans: physiology and clinical implications of autoregulation. Physiol Rev2021;
101: 1487–1559.
28.
GoelPKuceyeskiALoCastroE, et al.
Spatial patterns of genome-wide expression profiles reflect anatomic and fiber connectivity architecture of healthy human brain. Hum Brain Mapp2014;
35: 4204–4218.
29.
RichiardiJAltmannAMilazzoAC, et al.
BRAIN NETWORKS. Correlated gene expression supports synchronous activity in brain networks. Science2015;
348: 1241–1244.
30.
MorganSESeidlitzJWhitakerKJ, et al.
Cortical patterning of abnormal morphometric similarity in psychosis is associated with brain expression of schizophrenia-related genes. Proc Natl Acad Sci U S A2019;
116: 9604–9609.
31.
ZhangXGaoWCaoW, et al.
Cortical thickness alterations are associated with astrocytes and excitatory neuron-specific transcriptome signatures in pediatric bipolar disorder. Cereb Cortex2023;
33: 7540–7552.
32.
SunJXieYWangQ, et al.
Genes associated with grey matter volume reduction in multiple sclerosis. J Neurol2022;
269: 2004–2015.
33.
ArnatkeviciuteAFulcherBDFornitoA.A practical guide to linking brain-wide gene expression and neuroimaging data. NeuroImage2019;
189: 353–367.
34.
LongJLiJXieB, et al.
Morphometric similarity network alterations in COVID-19 survivors correlate with behavioral features and transcriptional signatures. NeuroImage Clin2023;
39: 103498.
35.
IkramMAZonneveldHIRoshchupkinG, et al.
Heritability and genome-wide associations studies of cerebral blood flow in the general population. J Cereb Blood Flow Metab2018;
38: 1598–1608.
36.
Excellence NIfHaC. National institute for health and care excellence: Clinical guidelines. COVID-19 rapid guideline: managing the long-term effects of COVID-19.
London:
National Institute for Health and Care Excellence (NICE), 2020.
37.
AmbarkiKWåhlinAZarrinkoobL, et al.
Accuracy of parenchymal cerebral blood flow measurements using pseudocontinuous arterial spin-labeling in healthy volunteers. AJNR Am J Neuroradiol2015;
36: 1816–1821.
38.
ShermanBTHaoMQiuJ, et al.
DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res2022;
50: W216–W221.
39.
DoughertyJDSchmidtEFNakajimaM, et al.
Analytical approaches to RNA profiling data for the identification of genes enriched in specific cells. Nucleic Acids Res2010;
38: 4218–4230.
40.
XuXWellsABO’BrienDR, et al.
Cell type-specific expression analysis to identify putative cellular mechanisms for neurogenetic disorders. J Neurosci2014;
34: 1420–1431.
41.
GordonDEJangGMBouhaddouM, et al.
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature2020;
583: 459–468.
42.
ArdellierFDBalogluSSokolskaM, SFNR-COVID groupet al.
Cerebral perfusion using ASL in patients with COVID-19 and neurological manifestations: a retrospective multicenter observational study. J Neuroradiol2023;
50: 470–481.
43.
AntonyARHaneefZ.Systematic review of EEG findings in 617 patients diagnosed with COVID-19. Seizure2020;
83: 234–241.
44.
KasASoretMPyatigoskayaN, et al.
The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur J Nucl Med Mol Imaging2021;
48: 2543–2557.
45.
GoehringerFBruyereADoyenM, et al.
Brain (18)F-FDG PET imaging in outpatients with post-COVID-19 conditions: findings and associations with clinical characteristics. Eur J Nucl Med Mol Imaging2023;
50: 1084–1089.
46.
MatschkeJLütgehetmannMHagelC, et al.
Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol2020;
19: 919–929.
47.
GagliardiSPoloniETPandiniC, et al.
Detection of SARS-CoV-2 genome and whole transcriptome sequencing in frontal cortex of COVID-19 patients. Brain Behav Immun2021;
97: 13–21.
48.
ZhouSWeiTLiuX, et al.
Causal effects of COVID-19 on structural changes in specific brain regions: a mendelian randomization study. BMC Med2023;
21: 261.
49.
SinghKKChaubeyGChenJY, et al.
Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis. Am J Physiol Cell Physiol2020;
319: C258–C267.
50.
KumariDSinghYSinghS, et al.
Mitochondrial pathogenic mutations and metabolic alterations associated with COVID-19 disease severity. J Med Virol2023;
95: e28553.
51.
KaundalRKKalvalaAKKumarA.Neurological implications of COVID-19: Role of redox imbalance and mitochondrial dysfunction. Mol Neurobiol2021;
58: 4575–4587.
52.
StefanoGBPtacekRPtackovaH, et al.
Selective neuronal mitochondrial targeting in SARS-CoV-2 infection affects cognitive processes to induce ‘brain fog’ and results in behavioral changes that favor viral survival. Med Sci Monit2021;
27: e930886.
53.
ArtusiCARomagnoloALeddaC, et al.
COVID-19 and Parkinson’s disease: What do We know so far?J Parkinsons Dis2021;
11: 445–454.
54.
SalariMEtemadifarMAshrafiF, et al.
Parkinson’s disease patients may have higher rates of covid-19 mortality in Iran. Parkinsonism Relat Disord2021;
89: 90–92.
55.
SmadiMKaburisMSchnapperY, et al.
SARS-CoV-2 susceptibility and COVID-19 illness course and outcome in people with pre-existing neurodegenerative disorders: systematic review with frequentist and bayesian meta-analyses. Br J Psychiatry2023;
223: 348–361.
56.
LiCLiuJLinJ, et al.
COVID-19 and risk of neurodegenerative disorders: a mendelian randomization study. Transl Psychiatry2022;
12: 283.
57.
ZhaoHZhangQChenH, et al.
Integrated multi-omics approach identified molecular mechanism and pathogenetic processes of COVID-19 that affect patient with parkinson’s disorder. Saudi J Biol Sci2021;
28: 6939–6945.
58.
D’ArrigoJS.Nanotargeting of drug(s) for delaying dementia: Relevance of covid-19 impact on dementia. Am J Alzheimers Dis Other Demen2020;
35: 1533317520976761.
59.
ShiYLiuWYangY, et al.
Exploration of the shared molecular mechanisms between COVID-19 and neurodegenerative diseases through bioinformatic analysis. Int J Mol Sci2023;
24: 24.
60.
ZorecRVerkhratskyA.Astrocytes in the pathophysiology of neuroinfection. Essays Biochem2023;
67: 131–145.
61.
SteardoLSteardoLJr.ZorecR, et al.
Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19. Acta Physiol (Oxf)2020;
229: e13473.
62.
MurtaVVillarrealARamosAJ.Severe acute respiratory syndrome coronavirus 2 impact on the Central nervous system: Are astrocytes and microglia main players or merely bystanders?ASN Neuro2020;
12: 1759091420954960.
63.
BarkLLarssonIMWallinE, et al.
Central nervous system biomarkers GFAp and NfL associate with post-acute cognitive impairment and fatigue following critical COVID-19. Sci Rep2023;
13: 13144.
64.
Fernández-CastañedaALuPGeraghtyAC, et al.
Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain. bioRxiv2022;
65.
KarsidagSSahinSAtesMF, et al.
Demyelinating disease of the Central nervous system concurrent with COVID-19. Cureus2021;
13: e17297.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
